Epilepsy and the risk of COVID-19-related hospitalization and death: A population study
- PMID: 38441374
- DOI: 10.1111/epi.17910
Epilepsy and the risk of COVID-19-related hospitalization and death: A population study
Abstract
Objective: People with epilepsy (PWE) may be at an increased risk of severe COVID-19. It is important to characterize this risk to inform PWE and for future health and care planning. We assessed whether PWE were at higher risk of being hospitalized with, or dying from, COVID-19.
Methods: We performed a retrospective cohort study using linked, population-scale, anonymized electronic health records from the SAIL (Secure Anonymised Information Linkage) databank. This includes hospital admission and demographic data for the complete Welsh population (3.1 million) and primary care records for 86% of the population. We identified 27 279 PWE living in Wales during the study period (March 1, 2020 to June 30, 2021). Controls were identified using exact 5:1 matching (sex, age, and socioeconomic status). We defined COVID-19 deaths as having International Classification of Diseases, 10th Revision (ICD-10) codes for COVID-19 on death certificates or occurring within 28 days of a positive SARS-CoV-2 polymerase chain reaction (PCR) test. COVID-19 hospitalizations were defined as having a COVID-19 ICD-10 code for the reason for admission or occurring within 28 days of a positive SARS-CoV-2 PCR test. We recorded COVID-19 vaccinations and comorbidities known to increase the risk of COVID-19 hospitalization and death. We used Cox proportional hazard models to calculate hazard ratios.
Results: There were 158 (.58%) COVID-19 deaths and 933 (3.4%) COVID-19 hospitalizations in PWE, and 370 (.27%) deaths and 1871 (1.4%) hospitalizations in controls. Hazard ratios for COVID-19 death and hospitalization in PWE compared to controls were 2.15 (95% confidence interval [CI] = 1.78-2.59) and 2.15 (95% CI = 1.94-2.37), respectively. Adjusted hazard ratios (adjusted for comorbidities) for death and hospitalization were 1.32 (95% CI = 1.08-1.62) and 1.60 (95% CI = 1.44-1.78).
Significance: PWE are at increased risk of being hospitalized with, and dying from, COVID-19 when compared to age-, sex-, and deprivation-matched controls, even when adjusting for comorbidities. This may have implications for prioritizing future COVID-19 treatments and vaccinations for PWE.
Keywords: electronic health records; health care utilization; real world evidence; routinely collected data.
© 2024 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Similar articles
-
Health care utilization and mortality for people with epilepsy during COVID-19: A population study.Epilepsia. 2024 May;65(5):1394-1405. doi: 10.1111/epi.17920. Epub 2024 Mar 5. Epilepsia. 2024. PMID: 38441332
-
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.J Infect. 2023 Apr;86(4):352-360. doi: 10.1016/j.jinf.2023.02.012. Epub 2023 Feb 10. J Infect. 2023. PMID: 36773891 Free PMC article.
-
COVID-19 vaccination uptake in people with epilepsy in wales.Seizure. 2023 May;108:49-52. doi: 10.1016/j.seizure.2023.04.006. Epub 2023 Apr 6. Seizure. 2023. PMID: 37080124 Free PMC article.
-
Risk of hospitalization and death for COVID-19 in persons with epilepsy over a 20-month period: The EpiLink Bologna cohort, Italy.Epilepsia. 2022 Sep;63(9):2279-2289. doi: 10.1111/epi.17356. Epub 2022 Jul 17. Epilepsia. 2022. PMID: 35778963 Free PMC article.
-
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2. Cochrane Database Syst Rev. 2021. PMID: 33624299 Free PMC article.
Cited by
-
Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.Lancet Public Health. 2025 Mar;10(3):e203-e227. doi: 10.1016/S2468-2667(24)00302-5. Epub 2025 Feb 24. Lancet Public Health. 2025. PMID: 40015291 Free PMC article.
-
Hospital outcomes of acute COVID-19 infection among patients with neurological conditions: a single-center study.Front Neurol. 2024 Jul 10;15:1434046. doi: 10.3389/fneur.2024.1434046. eCollection 2024. Front Neurol. 2024. PMID: 39050126 Free PMC article.
References
REFERENCES
-
- (WHO) WHO. WHO Coronavirus (COVID‐19) Dashboard 2022. [cited 2022 Sep 1]. Available from: https://covid19.who.int/.
-
- Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess mortality due to the COVID‐19 pandemic: a systematic analysis of COVID‐19‐related mortality, 2020–21. Lancet. 2022;399(10334):1513–1536.
-
- Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID‐19 pandemic. Lancet. 2021;398(10312):1700–1712.
-
- Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post‐acute sequelae of COVID‐19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157–1172.
-
- World Health Organization. Epilepsy: a public health imperative: summary. Geneva: World Health Organization; 2019 Contract No.: WHO/MSD/MER/19.2.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
